This site is intended for U.S. HCPs only

Spotlight Series Online Training

Welcome to Online Training for Healthcare Professionals

Here you'll watch a video overview of CUVITRU [Immune Globulin Subcutaneous (Human)] 20% solution and its administration for patients with primary humoral immunodeficiency (PI). The 10 short video sections are provided to help give you the tools to train patients and caregivers.

Watch the 10 sections in consecutive order, which will take about 40 minutes total

Take a 10-question quiz, which will take about 10 minutes

After passing the quiz (80% or higher), you can download a personalized Certificate of Completion

Start Your Training

IMPORTANT: Please set aside about an hour to complete the training and short quiz. We recommend setting aside enough time to complete the training and quiz in one session. (Training progress can only be stored if you have cookies enabled and access the training from the same device and browser.)

For additional training and PI support, please see the Shire resources below

Watch the CUVITRU Step-by-Step Administration Video

The CUVITRU Step-by-Step Administration Video provides instruction on how to properly infuse CUVITRU.

Watch Video >

Download the CUVITRU Step-by-Step Administration Guide

The CUVITRU Step-by-Step Administration Guide instructs patients on the proper administration of CUVITRU.

Download Guide >

Get Support for You and Your Patients with MyIgSource

MyIgSource gives you the resources and support you need to provide the best possible care for your patients.

Visit >

Please expand for Indication and Important Safety Information
Please see the Full Prescribing Information including Boxed Warning regarding Thrombosis.


Indication and Important Safety Information
CUVITRU [Immune Globulin Subcutaneous (Human)] 20% Solution


CUVITRU is an Immune Globulin Subcutaneous (Human) (IGSC), 20% Solution indicated as replacement therapy for primary humoral immunodeficiency (PI) in adult and pediatric patients two years of age and older.

CUVITRU is for subcutaneous infusion only.

Important Safety Information


Thrombosis may occur with immune globulin products, including CUVITRU. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling vascular catheters, hyperviscosity and cardiovascular risk factors.

For patients at risk of thrombosis, administer CUVITRU at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk of hyperviscosity.


CUVITRU is contraindicated in patients who have had an anaphylactic or severe systemic hypersensitivity reaction to the subcutaneous administration of human immune globulin and in IgA-deficient patients with antibodies against IgA and a history of hypersensitivity to human immune globulin treatment.


Hypersensitivity: Severe hypersensitivity reactions may occur, even in patients who have tolerated previous treatment with human immune globulin. IgA-deficient patients with antibodies to IgA are at greater risk of developing potentially severe hypersensitivity and anaphylactic reactions.

Renal Dysfunction/Failure: Monitor renal function and urine output and consider lower, more frequent dosing in patients who are at risk of developing renal dysfunction because of pre-existing renal insufficiency or predisposition to acute renal failure.

Thrombosis: Monitor for signs and symptoms of thrombosis and assess blood viscosity for those at risk for hyperviscosity.

Aseptic Meningitis Syndrome (AMS): Monitor for clinical signs and symptoms of AMS.

Hemolysis: Monitor for clinical signs and symptoms of hemolysis and delayed hemolytic anemia.

Transfusion-Related Acute Lung Injury (TRALI): Monitor for pulmonary adverse reactions associated with TRALI.

Transmittable Infectious Agents: Because CUVITRU is made from human plasma, it may carry a risk of transmitting infectious agents, such as viruses and other pathogens. No confirmed cases of transmission of viral diseases or variant Creutzfeldt-Jakob disease (vCJD) have been associated with CUVITRU.

Interference with Laboratory Tests: False positive serological test results, with the potential for misleading interpretation, may occur as the result of passively transferred antibodies.


The most common adverse reactions observed in clinical trials in ≥5% of patients were: local adverse reactions, systemic adverse reactions including headache, nausea, fatigue, diarrhea, and vomiting.

Please see the Full Prescribing Information including Boxed Warning regarding Thrombosis.